These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 9268175

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S.
    Arch Intern Med; 1993 Jul 12; 153(13):1541-6. PubMed ID: 8391792
    [Abstract] [Full Text] [Related]

  • 6. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D.
    Thromb Haemost; 1994 Aug 12; 72(2):186-90. PubMed ID: 7831649
    [Abstract] [Full Text] [Related]

  • 7. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H, Marchetti O, Haeberli A, Mombelli G.
    Thromb Haemost; 1999 Oct 12; 82(4):1227-31. PubMed ID: 10544903
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.
    N Engl J Med; 2001 Mar 01; 344(9):626-31. PubMed ID: 11228276
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
    Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E.
    Thromb Haemost; 1992 Jul 06; 68(1):14-8. PubMed ID: 1325076
    [Abstract] [Full Text] [Related]

  • 13. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM.
    Semin Thromb Hemost; 2001 Oct 06; 27(5):513-8. PubMed ID: 11668421
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
    Thromb Haemost; 1991 Mar 04; 65(3):251-6. PubMed ID: 1646490
    [Abstract] [Full Text] [Related]

  • 18. Practicability and quality of outpatient management of acute deep venous thrombosis.
    Blättler W, Kreis N, Blättler IK.
    J Vasc Surg; 2000 Nov 04; 32(5):855-60. PubMed ID: 11054216
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.